About RestoriT
Rapid Transition to Late Stage Proof of Concept
RestoriT’s primary goal is to realise a return on investment by improving performance of either existing, approved prescription drugs or late development stage drug candidates
Drug performance will be enhanced by:
– Applying novel, proprietary formulations and/or
– Positioning RTL drugs in specific patient populations with poorly met medical needs
IP protection is derived from:
– Formulation patents and/or
– Use patents and/or
– Regulatory in-market protection e.g. orphan drug designation
Our clinical focus is andrology and co-morbidities of metabolic disease – fields well known to the founding team and fields in which clinical trials can run quickly with well established endpoints. Products will be developed and value realised by driving programs through to either proof of efficacy studies or registration studies. The company will be agile and reduce operating costs by utilising an outsourcing model.
| Project | Field | Indication | Route of Admin. | Formulation & CMC | Proof of Concept | Phase II (efficacy study) | Pivotal Study |
| QPD101 | Andrology, supportive care | Erectile dysfunction post radical prostatectomy | Injection | 2021 | ➡️ | ➡️ | 2023 |
| QPD102 | Diabetes Supportive care | Erectile dysfunction, PDE5i refractory patients | Transdermal | 2021 | ➡️ | 2023 | |
| QPD201 | Metabolic disease | Obesity/metabolic syndrome | Oral |
3rd party |
➡️ | 2023 | |
| QPD301 | Muscle spasm | Restless leg syndrome | Topical | 3rd party in-license |
➡️ | 2023 | |
| QPD401 | Urology | Interstitial cystitis | Topical | 3rd party in-license |
➡️ | 2023 |
Our team
Leadership & Management
Professor Mike Wyllie
Founder
Prof. Wyllie has greater than 30 years of experience in senior management level positions within the pharmaceutical industry including American Home Products and Pfizer; Chief Science Officer or Scientific Advisor (Regent Pacific Ltd., Zi Medical plc., Xention Ltd., Taihua Plc.; Director (Bactomed, Ltd., Glycomar, Ltd.), Director (Morvus Ltd and Gordian Ltd). He has considerable hands-on experience in all aspects of the drug discovery and development process and has been involved with new project inception, drug discovery and safety testing, early and late-stage clinical development, regulatory filing and the successful commercialization of products including Viagra® (sildenafil). He was an assistant editor of the British Journal of Urology in the Sexual Medicine Section. He served on the Clinical Trial Design and Future Therapies in BPH Committees of the World Health Organisation and the International Consultations on Urological Disease. Dr. Wyllie has authored over 100 publications and is named as the inventor of in excess of 90 patents.
Contact Us
We welcome enquiries regarding our pipeline and future licensing opportunities.